Forge Biologics’ clinical program, FBX-101, for patients with Krabbe disease has been discontinued
Message from Forge Biologics:
“After a holistic and strategic review, we have made the difficult decision to discontinue our development of the FBX-101 program. This was not an easy decision, and we recognize the impact this news will have on the Krabbe community and all those searching for an effective treatment for this devastating disease.
Through careful evaluation, we determined that Forge is no longer optimally positioned to progress and support the additional development needed to ensure the success of FBX-101. Advancing it further would require resources and expertise beyond our current scope as we focus on our core mission of advancing gene therapy manufacturing. We understand the impact this news has on the Krabbe community and all those searching for an effective treatment for this devastating disease.
While the clinical trial has been stopped, we are committed to responsibly winding down this program and will continue to provide support and appropriate follow-up and transition activities for patients who have been treated.”
To read the letter shared with the patient community: Forge Biologics letter
